Browse > Article
http://dx.doi.org/10.7314/APJCP.2013.14.1.81

Diagnostic Role of Survivin in Urinary Bladder Cancer  

Srivastava, Anupam Kumar (Department of Radiotherapy, King George's Medical Medical University)
Singh, Pankaj Kumar (Department of Radiotherapy, King George's Medical Medical University)
Srivastava, Kirti (Department of Radiotherapy, King George's Medical Medical University)
Singh, Dhramveer (Department of Urology, King George's Medical Medical University)
Dalela, Divakar (Department of Urology, King George's Medical Medical University)
Rath, Srikanta Kumar (Genotoxicity Laboratory, Division of Toxicology, Central Drug Research Institute)
Goel, Madhu Mati (Department of Pathology, King George's Medical Medical University)
Bhatt, Madan Lal Brahma (Department of Radiotherapy, King George's Medical Medical University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.14, no.1, 2013 , pp. 81-85 More about this Journal
Abstract
Background: Early diagnosis of carcinoma of bladder remains a challenge. Survivin, a member of the inhibitor of apoptosis (IAP) protein family, is frequently activated in bladder carcinoma. The objective of this study was to investigate urinary survivin as a marker for diagnosis of urinary bladder. Materials and Methods: We examined urinary survivin concentration in 28 healthy individuals, 46 positive controls and 117 cases of histologically proven TCC prior to transurethral resection, using ELISA, and compared values with findings for urinary cytology. Results: Survivin was found to be significantly higher in the cancer group (P<0.05). A cut off value of 17.7 pg/ml was proposed, with an approximate sensitivity of 82.9% and specificity of 81.1% (P<0.0001), whereas urine cytology had a sensitivity of 66.7% and a specificity of 96.0%. Conclusions: Urinary survivin can be used as a non-invasive diagnostic biomarker for TCC bladder, both for primary and recurrent disease.
Keywords
Survivin; urinary bladder cancer; urinary biomarker; diagnosis;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Viv Bewick, Liz Cheek, Jonathan Ball (2004). Statistics review 13: Receiver operating characteristic curves. Critical Care, 8, 508-12.   DOI   ScienceOn
2 Wang T, Qian X, Liu B (2007). Survivin: potential role in diagnosis, prognosis and targeted therapy of gastric cancer. World J Gastroenterol, 13, 2784-90.
3 Weikert S, Christoph F, Schrader M, et al (2005) Quantitative analysis of survivin mRNA expression in urine and tumor tissue of bladder cancer patients and its potential relevance for disease detection and prognosis. Int J Cancer, 116, 100-04.   DOI   ScienceOn
4 Walsh PC, Retik Ab, Vaughn ED, et al (1997) Campbell's Urology. Philadelphia, WB Saunders, Co., 2354-57.
5 Agarwal PK, Black PC, Kamat AM (2008). Considerations on the use of diagnostic markers in management of patients with bladder cancer. World J Urol, 26, 39-44.   DOI
6 Ambrosini G, Adida C, Altieri D (1997). A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med, 3, 917-21.   DOI   ScienceOn
7 Altieri DC (2003). Survivin in apoptosis control and cell cycle regulation in cancer. Progress in Cell Cycle Res, 5, 447-52.
8 Azuhata T, Scott D, Takamizawa S, et al (2001). The inhibitor of apoptosis protein survivin is associated with high-risk behavior of neuroblastoma. J Pediatr Surg, 36, 1785-91.   DOI   ScienceOn
9 Boman H, Hedelin H, Holmang S, (2002). Four bladder tumor markers have a disappointingly low sensitivity for small size and low grade recurrence. J Urol, 16, 780-3.
10 Brown FM (2000). Urine cytology. It is still the gold standard for screening? Urol Clin North Am, 27, 25-37.   DOI   ScienceOn
11 Davido HT, Getzenberg RH (2002). Utilization of a urine-based assay for BLCA-4 in the detection of bladder cancer. J Clinical Ligand Assay, 25, 83-6.
12 Epstein JI, Amin MB, Reuter VR, et al (1998). The world health organization/international society of urological pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. bladder consensus conference committee. Am J Surg Pathol, 22, 1435-48.   DOI   ScienceOn
13 Fritz A, Percy C, Jack A, et al (2000). International Classification of Diseases for Oncology, 3rd edition, World Health Organization, Geneva.
14 Fuessel S, Kueppers B, Ning S, et al (2004). Systematic in vitro evaluation of survivin directed antisense oligodeoxynucleotides in bladder cancer cells. J Urol, 171, 2471-6.   DOI   ScienceOn
15 Grossfeld GD, Carroll PR (1998). Evaluation of asymptomatic microscopic hematuria. Urol Clin N Am, 25, 661-76.   DOI   ScienceOn
16 Goebell PJ, Groshen SL, Schmitz-Drager BJ (2008). Guidelines for development of diagnostic markers in bladder cancer. World J Urol, 26, 5-11.   DOI
17 Giodini A, Kallio MJ, Wall NR, et al (2002). Regulation of microtubule stability and mitotic progression by survivin. Cancer Res, 62, 2462-7.
18 Ikeguchi M, Kaibara N (2002). Survivin, messenger RNA expression is a good prognostic biomarker for oesophageal carcinoma. Bri J Cancer, 87, 883-7.   DOI   ScienceOn
19 Kausch I, Bohle A (2001). Bladder cancer. II. Molecular aspects and diagnosis. Eur Urol, 39, 498-506.   DOI   ScienceOn
20 Konety BR, Getzenberg RH (2001). Urine based markers of urological malignancy. J Urol, 165, 600-11.   DOI   ScienceOn
21 Lokeshwar VB, Soloway MS (2001). Current bladder tumor tests: does their projected utility fulfill clinical necessity? J Urol, 165, 1067-77.   DOI   ScienceOn
22 Ohsawa I, Nishimura T, kondo Y, et al (2004). Detection of urine survivin in 40 patients with bladder cancer. J Nippon Med Sch, 71, 379-83.   DOI
23 Rodel F, Hoffmann J, Grabenbauer GG, et al (2002). High survivin expression is associated with reduced apoptosis in rectal cancer and may predict disease-free survival after preoperative radiochemotherapy and surgical resection. Strahlenther Onkol, 178, 426-35.   DOI
24 Ryan BM, Konecny GE, Kahlert S, et al (2006). Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1. Ann Oncol, 17, 597-04.   DOI   ScienceOn
25 Siegel R, Ward E, Brawley O, Jemal A (2011). Cancer statistics, 2011. the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin, 61, 212-36.   DOI
26 Swana HS, Grossman D, Anthony JN, et al (1999). Tumor content of the antiapoptotic molecule SURVIVIN and recurrence of bladder cancer. N Engl J Med, 34, 1452-53.
27 Smith SD, Wheeler MA, Plescia J, et al (2001). Urine detection of survivin and diagnosis of bladder cancer. JAMA, 285, 324-8.   DOI   ScienceOn
28 Shariat SF, Casella R, Khoddami SM, et al (2004). Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer. Urol, 171, 626-30.   DOI   ScienceOn
29 Sobin LH, Wittekind CL (2002). TNM classification of malignant tumors, 6th edition. John Wiley & Sons, New York.
30 SUN Yi, HE Da-lin, MA Qiang, et al (2006). Comparison of seven screening methods in the diagnosis of bladder cancer. Chinese Med J, 119, 1763-71.
31 Sharp JD, Hausladen DA, Maher MG, et al (2002). Bladder cancer detection with urinary survivin, an inhibitor of apoptosis. Front Biosci, 7, 36-41.   DOI
32 Uren AG, Wong L, Pakusch M, et al (2000). Survivin and the inner centromere protein INCENP show similar cell-cycle localization and gene knockout phenotype. Curr Biol, 10, 1319-28.   DOI   ScienceOn